Research Notes

Stay informed with the most recent market and company research insights.

A man sitting at a table with a glass of orange juice.

Research Notes

Stable structure – now to build some growth

IRESS
3:27pm
February 24, 2025
IRE reported adjusted EBITDA of A$132.8m, +25% and in-line with expectations. Result composition was mixed, with the core AUS Wealth division down 13% HOH; offset by the UK +49%. Other divisions were relatively stable HOH. FY25 Adjusted EBITDA guidance was provided at A$127-135m (the bottom-end in-line with annualised 2H24 continuing ops performance). Whilst this points to modest growth, IRE is reinvesting cost savings (and higher capex) into revenue growth initiatives. The success of these is key to medium-term (FY26+) growth. IRE’s earnings are more defendable; free cash flow has improved; and the balance sheet strength adds longer-term optionality. In our view, the valuation point implies low growth persists, which provides a strong ‘option’ on management execution.

Outlook and balance sheet looking solid

SKS Technologies Group
3:27pm
February 24, 2025
SKS reported a strong 1H25 result, delivering NPAT of $5.8m (up 216% on the pcp), a ~13.7% beat vs MorgansF $5.1m. The company delivered solid PBT margin expansion and record cash generation, ending the period with cash of $19.6m. The group also upgraded its FY25 guidance and is now expecting PBT of ~$18.2m. We upgrade our FY25-27F EPS forecasts by 7%/5%/2% respectively to reflect the upgrade to SKS revised margin guidance. This sees our blended DCF/P/E-based price target increase to $2.30 (from $2.15) and we maintain our Add rating.

It’s now a 5-year marathon, not a sprint

NEXTDC
3:27pm
February 24, 2025
NXT’s 1H25 result and outlook were largely as expected. The key challenge for investors remains the tradeoff between NXT investing now to setup the business for a much greater size (higher OPEX now) and the fact that they are investing ahead of revenue growth (higher OPEX is a short-term EBITDA drag). NXT needs to execute well now, on commitments already made, to remain a preferred digital supplier, and continue benefiting from the decades of digital infrastructure growth which is yet to come. Incidentally, a ~$200m+ increase in revenue is already contracted so this is just a timing challenge. We see building a solid foundation as the best way to create value, but acknowledge it can create a jittery investor base, in the short term. Add retained, PT reduced to $18.80.

1H25 Result: Getting comfortable

Adairs
3:27pm
February 24, 2025
Adairs’ 1H25 result was broadly in line with our expectations, with underlying EBIT (pre-AASB 16) up 10% to $33.0m. This was driven by strong sales in Adairs and Mocka Australia, offset by weakness in Focus and Mocka NZ. Margins were well managed driven by cost efficiencies from the National Distribution Centre (NDC) and implementation of the new warehouse management system. The positive trading momentum in Adairs has continued into the second half with sales up an impressive 15.2%; we expect this to moderate for the balance of the half. Ongoing efficiencies in the NDC will help offset inflationary cost pressures and margin headwinds. We forecast EBIT for Adairs brand just shy of 10%. We have revised our EBIT down 3% and 4% respectively, but have increased our price target 10c to $2.85 based on higher peer multiples. We retain our ADD rating.

1H25 Result: Don’t dream it’s over

Lovisa
3:27pm
February 24, 2025
The pace of store rollout has started to accelerate after a period of consolidation, notably in the US over the past two years. We believe Lovisa is poised to hit the landmark of 1,000 stores before the end of the current half, possibly by the time the outgoing CEO Victor Herrero hands over the reins on 31 May. This underscores what we see as the most important element of the Lovisa investment case: the business has a subscale presence in almost every one of the 50 markets in which it operates and significant long-term growth potential in each. We believe the platform for long-term growth is getting stronger all the time. We reiterate our ADD rating. Our target price moves from $36 to $35. LFL sales in 1H25 were less than we had expected at +0.1% (MorgansF: +1.0%) but accelerated to +3.7% in the first 7 weeks of 2H25. This flowed through to 3% lower EBIT than forecast, despite gross margins exceeding our estimate by 90 bps. Lead coverage of Lovisa transfers to Emily Porter with this note.

Trading opportunity emerges with share price fall

Polynovo
3:27pm
February 24, 2025
PNV posted its 1H25 result which was in line with expectations. However, the share price fell sharply (down 8%) which we found surprising and believe has created a buying opportunity. Our forecast growth of 29% for FY25 appears achievable driven by regional expansion and additional indications. We have made no changes to forecasts or TP. Add recommendation maintained.

It’s still tough out there

Reece
3:27pm
February 24, 2025
REH’s 1H25 result was slightly weaker than expected with the housing outlook in both ANZ and the US remaining soft. Key positive: Balance sheet remains healthy with ND/EBITDA (ex-leases) at 0.8x, leaving capacity for ongoing growth investments that will benefit the business over the long term. Key negatives: Volumes and margins were lower in both ANZ and the US; Increased competition has led to market share loss in the US; Cost inflation remains a headwind. We decrease FY25-27F EBITDA by between 2-3%. Our target price falls to $18.70 (from $19.95) and with a 12-month forecast TSR of -1%, we upgrade our rating to Hold (from Reduce). While we continue to see REH as a good business with a strong culture and long track record of growth, the outlook for housing in the near-term remains uncertain despite a likely peak in central bank interest rates in both Australia and the US. REH will also need to respond to aggressive competition in the US, which also adds to the uncertainty on the earnings outlook.

All weather steel cycle performance, with yield

Stanmore Resources
3:27pm
February 24, 2025
Key CY24 financials beat our expectations driven by better realisations/ revenues. The US 6.7c dividend was a positive surprise, helped by a robust balance sheet and a material step down in 2025 capex as internal investment completes. CY25 guidance was materially better than our conservative expectations. SMR trades at ~0.65x P/NPV reflecting depressed investor interest and opacity in the global steel outlook. With a robust balance sheet, and dividends through the cycle, we think SMR offers a compelling option over steel market upside in time for patient investors.

Will organisational reshuffles

Ramsay Health Care
3:27pm
February 24, 2025
Since taking over the reins last Dec, CEO Natalie Davis has started running a ruler over operations, flagging senior leadership changes, updating the operational structure and writing down goodwill related to Elysium mental health business in the UK. Preliminary 1HFY25 results have also been released, which sees underlying operating income decline 1-3% on pcp, and management no longer expecting NPAT growth in FY25. At this early stage, it is difficult to assess if adjustments in operational strategy will have the desired impact, so we continue to remain cautious. We adjust FY25-27 earnings lower, mainly in out years, with our price target decreasing to A$37.74. Hold. CFO Martyn Roberts and Australia CEO Carmel Monaghan will be exiting stage left, with Mr Roberts resigning to “pursue other opportunities” and Ms Monaghan retiring mid-2025. Both will remain with the company during a transition phase. An updated operational structure, which aims to “strengthen the group’s focus on its core Australian hospital business, while building the capabilities necessary to drive transformation and shareholder value”, is slated to be implemented by mid-25 with key changes including: RHC will take a A$291m post-tax goodwill impairment of Elysium, driven by continued occupancy challenges in mental health rehabilitation and neurological services, as well as a slower than planned ramp up in occupancy at new site, partially offset by the increase in valuation for UK Hospitals driven by an improved tariff outlook in 2004/05 and public/private partnership momentum. In an attempt to improve Elysium’s performance, a COO commended in Jan-25, targeting “operational rigour” with a “focus on financial outcomes”. In addition, consultants have been hired to “identify initiatives to improve profitability”. A A$64.5m tax liability provision release for Ramsay Santé will also be taken, as the time period to hold the provision has lapsed.

NEU adds another two zombie designations

Neuren Pharmaceuticals
3:27pm
February 24, 2025
NEU has announced the granting of FDA’s Rare Pediatric Disease Designation (RPD) for both Pitt Hopkins (PH) and Angelman Syndrome (AS), both neurological disorders which emerge in early childhood and currently have no approved treatments. These designations allow companies to apply for various incentives, including the highly-prized Priority Review Voucher (PRV) which awards RPD participants a voucher which can be used to accelerate the FDA’s review process, or can opt to on-sell to another drug developer to use. However, there remains uncertainty under current legislation where the PRV program was active up until September 2024 but has not since been reauthorised. The sunsetting of incentives currently only allows the awarding of the vouchers for approved designations up until late 2026, but seemingly not the qualifying tickets to entry which it continues to award. Given the time it takes to run Ph3 pivotal trials along with the NDA submission process, the designations are effectively zombie designations with no material benefit unless US congress reauthorise the program. A bill introduced in December 2024 (with bipartisan support) which would have extended the sunset date for another 4+ years ran into political challenges and ultimately stripped back many provisions which included the PRV extension. We note that congress has since passed several of the bills originally stripped out of the continuing resolutions, which gives some degree of hope for the program in the near-term. However, from our searches we cannot find any current commentary from the FDA or heard of this program being on the ticket for discussion at the congressional level at this stage.

News & Insights

The U.S. and China, through negotiations led by the Chinese Deputy Premier and U.S. Treasury Secretary Scott Bessent, agreed to a 90-day tariff reduction from over 125% to 30% and 10% respectively

US and Chinese actions had led to an unintended embargo of trade between the world’s two largest economies.

In recent days there has been discussion of the temporary “cease fire” in the tariff war between the US and China.

The situation was that both countries had levied tariffs on each other more than 125%. This had led to a mutual embargo of trade between the two world is two largest economies. Then as a result of negotiation between the Deputy Premier of China and US Treasury Secretary Scott Bessent both China and the US agreed to a 90 day pause in “hostilities” where both sides agreed to reduce the US tariff on the China to 30 percent and the Chinese tariff on the US to 10%.

Some suggested that this meant that “China had won” others suggested that the “US had won.” To us this really suggests that both parties were playing in a different game. The was a game in which both sides had won.

To understand why this is the case we must understand a little of the theory of this type of competition. Economists usually use discuss competition in terms of markets where millions of people are involved. In such a case we find a solution by finding the intersection of supply and demand which model the exchange between vast numbers of people.

But here we are ware talking of a competition where only two parties are involved.

When exceedingly small numbers like this are involved, we find the solution to the competition by what is called “Game Theory.”

In this game there are only two players. One is called China, and the other is called the US. Game theory teaches us that are there three different types of games. The first is a zero-sum game. In this game there two sides are competing over a fixed amount of product. Again, this is called " A zero sum game “. Either one party gets a bigger share of the total sum at stake and the other side gets less. This zero-sum game is how most of the Media views the competition between the US and China.

A second form is a decreasing sum game. An example of this is a war. Some of the total amount that is fought over is destroyed in the process. Usually both sides will wind up worse than when they started.

Then there is a third form. This form is called an ‘increasing sum game.’ This is where both sides cooperate so that the total sum in the game grows because of this cooperation. We think that what happened in the US and China negotiation was an increasing sum game.

As Scott Bessent said at the Saudi Investment Forum in Riyadh soon after the agreement was signed, “both sides came with a clear agenda with shared interests and great mutual respect.”

He said, “after the weekend, we now have a mechanism to avoid escalation like we had before. We both agreed to bring the tariff levels down by 115% which I think is very productive because where we were with 145% and 125% was an unintended embargo. That is not healthy for the two largest economies in the world.”

He went on, “when President Trump began the tariff program, we had a plan, we had a process. What we did not have with the Chinese was a mechanism. The Vice Premier and I now call this the ‘Geneva mechanism’”.

Both sides cooperated to make both sides better off. Bessent added “what we do not want, and both sides agreed, is a generalised decoupling between the two largest economies in the world. What we want is the US to decouple in strategic industries, medicine, semiconductors, other strategic areas. As to other countries; we have had very productive discussions with Japan, South Korea, Indonesia, Taiwan, Thailand. Europe may have collective action problems with the French wanting one thing and the Italians wanting a different thing. but I am confident that with Europe, we will arrive at a satisfactory conclusion.

We have a very good framework. I think we can proceed from here.”

What we think we can see here is that the United States and China have cooperated to both become better off. This is what we call an increasing sum game.

They will continue their negotiation using that approach. This will do much to allay the concerns that so many had about the effect of these new tariffs.

Read more
Treasury Secretary Scott Bessent’s adept negotiation of a US-China tariff deal and his method for assessing tariffs’ modest impact on inflation, using a 20.5% effective rate, position him as a formidable successor to Henry Morganthau’s legacy.

In the 1930s, the US Treasury Secretary Henry Morganthau was widely regarded as the finest Treasury Secretary since Alexander Hamilton. However, if the current Treasury Secretary Scott Bessent, continues to deliver results as he is doing now, he will provide formidable competition to Morganthau’s legacy.

The quality of Bessent’s work is exceptional, demonstrated by his ability to secure an agreement with China in just a few days in complex circumstances.

The concept of the "effective tariff rate" is a term that has gained traction recently. Although nominal tariff rates on individual goods in individual countries might be as high as 100% or 125%; the effective tariff rate, which reflects the actual tariffs the US imposes on imports from all countries, is thought to be only 20.5%. This figure comes from an online spreadsheet published by Fitch Ratings, since 24 April.

Finch Ratings Calculator Screenshot

This effective tariff rate of 20.5% can be used in assessing the impact of import tariffs on US inflation. To evaluate this, I used a method proposed by Scott Bessent during his Senate confirmation hearing. Bessent began by noting that imports account for only 16% of US goods and services that are consumed in the US Economy. In this case, a 10% revenue tariff would increase domestic prices by just 1.6%. With a core inflation rate of 2.8% in the US, this results in a headline inflation rate of 4.4%. Thus, the overall impact of such tariffs on the US economy is relatively modest.

A couple of weeks ago, Austan Goolsbee, the President of the Chicago Fed, noted that tariffs typically increase inflation, which might prompt the Fed to lift rates, but they also reduce economic output, which might prompt the Fed to rate cuts. Consequently, Goolsbee suggested that the Federal Reserve might opt to do nothing. This prediction was successful when the Open Market Committee of the Fed, with Goolsbee as a member, left the Fed Funds rate unchanged last week.

A 90-day agreement between the US and China, masterfully negotiated by Scott Bessent, has dramatically reduced tariffs between China and the US. China now only imposes a 10% import tariff on the US, while the US applies a 30% tariff on Chinese goods—10% as a revenue tariff and 20% to pressure China to curb the supply of fentanyl ingredients to third parties in Mexico or Canada. It is this fentanyl which fuels the US drug crisis. This is a priority for the Trump administration.

How Import Tariffs Affect US Inflation.

We can calculate how much inflation a tariff adds to the US economy in the same way as Scott Bessent by multiplying the effective tariff rate by the proportion that imports are of US GDP. Based on a 20.5% US effective tariff rate, I calculated that it adds 3.28% to the US headline Consumer Price Index (CPI). This results in a US headline inflation rate of 6.1% for the year ahead. In Australia, we can draw parallels to the 10% GST introduced 24 years ago, where price effects were transient and vanished after a year, avoiding sustained high inflation.

Before these negotiations, the US was levying a nominal tariff on China of 145%. Some items were not taxed, so meant that the effective tariff on China was 103%. Levying this tariff meant that the US faced a price effect of 3.28%, contributing to a 6.1% headline inflation rate.

If the nominal tariff rate dropped to 80%, the best-case scenario I considered previously, the price effect would fall to 2.4%, with a headline US inflation rate of 5.2%. With the US now charging China a 30% tariff, this adds only 2% to headline inflation, yielding a manageable 4.8% US inflation rate.

As Goolsbee indicated, the Fed might consider raising interest rates to counter inflation or cutting them to address reduced output, but ultimately, it is likely to maintain current rates, as it did last week. I anticipate the Fed will continue to hold interest rates steady but with an easing bias, potentially cutting rates in the second half of the year once the situation stabilises.

My current Fed Funds rate model suggests that, absent this year's tariff developments, the Fed would have cut rates by 50 basis points. This could be highly positive for the US economy.

Read more
In a lively presentation to the Economic Club of New York, Federal Reserve Bank of Chicago President Austan Goolsbee highlighted tariffs as a minor stagflation risk but emphasized strong U.S. GDP growth of around 2.6%, suggesting a resilient economy and potential for a soft landing.

I’d like to discuss a presentation delivered by Austan Goolsbee, President of the Federal Reserve Bank of Chicago, to the Economic Club of New York on 10 April. Austan Goolsbee, gave a remarkably animated talk about tariffs and their impact on the U.S. economy.

Goolsbee is a current member of the Federal Reserve’s Open Market Committee, alongside representatives from Washington, D.C., and Fed bank Presidents from Chicago, Boston, St. Louis, and Kansas City.  

Having previously served as Chairman of the Council of Economic Advisers in the Obama White House, Goolsbee’s presentation style in New York was notably different from his more reserved demeanour I had previously seen when I had attended a talk of his in Chicago.

During his hour-long, fast-paced talk, Goolsbee addressed the economic implications of tariffs. He recounted an interview where he argued that raising interest rates was not the appropriate response to tariffs, a stance that led some to label him a “Dove.” He humorously dismissed the bird analogy, instead likening himself to a “Data Dog,” tasked with sniffing out the data to guide decision-making.

Goolsbee explained that tariffs typically drive inflation higher, which might ordinarily prompt rate hikes. However, they also tend to reduce economic growth, suggesting a need to cut rates. This creates a dilemma where rates might not need adjustment at all. He described tariffs as a “stagflation event” but emphasised that their impact is minor compared to the severe stagflation of the 1970s.

When asked if the U.S. was heading towards a recession, Goolsbee said that the "hard data" was surprisingly strong.

Let us now look at our model of US GDP based on the Chicago Fed National Activity Index. This Index   incorporates 85 variables across production, sales, employment, and personal consumption.  In the final quarter of last year, this index indicated the GDP growth was slightly below the long-term average, suggesting a US GDP growth rate of 1.9% to 2%.

However, data from the first quarter of this year showed stronger growth, just fractionally below the long-term trend.

Using Our Chicago Fed model, we find that US GDP growth had risen from about 2% growth to a growth rate of around 2.6%, indicating a robust U.S. economy far from recessionary conditions.

Model of US GDP

We think that   increased government revenue from Tariffs might temper domestic demand, potentially guiding growth down towards 1.9% or 2% by year’s end. Despite concerns about tariffs triggering a downturn, this highlights the economy’s resilience and suggests   a “soft landing,” which could allow interest rates to ease, weaken the U.S. dollar, and boost demand for equities.

We will provide monthly reviews of these indicators. We note that, for now, the outlook for the U.S. economy remains very positive.

Read more